Development and Market Objectives

Development of bispecific antibody inhibiting TNF- α and IL-17, which doing important role in autoimmune and autoinflammatory diseases.

Unmet Medical Need & Target Patients

- Focusing on ankylosing spondylitis and psoriatic arthritis. Especially, ankylosing spondylitis is considered as rare disease. That helps accelerating development.

- The response rate of TNF- α blockade on ankylosing spondylitis is less than 50%. The response rate of IL-17 blockade is much lower than that of TNF-a blockade.

Current Progress

- Developmental candidates are selected

- RCB in preparation

Intellectual Property

- Patent on novel IL-17 antibody was applied and PCT application is scheduled on early December 2017

Competitive Advantages

- One shot Two kill: response rate & Disease modifying compared to TNF- α, IL-17a blockade

- May applied to Non-responder to TNF- α blockade

- Easy to treatment & low cost compared to combination therapy

- May be a choice for TNF- α blockade discontinuation

Disease Target

autoimmune disease

Project duration

Dec. 9, 2016 ~ Mar. 8, 2018

Organization

Y-Biologics Inc.

Phase of Development

Optimization

Contact

• Organization: Y-Biologics Inc.
• Website: http://www.ybiologics.com
• Contact Person: Young-Gyu Cho
• E-mail: younggyucho@ybiologics.com
• Phone No.: 82-42-716-4979

Related Projects